News | Stents Drug Eluting | October 27, 2015

PANDA III Trial Compares Drug-Eluting Stents With Bioresorbable Polymers

SinoMed’s BuMA SES found non-inferior to Excel DES, fully eluting sirolimus within 30 days and dissolving polymer within three months

October 27, 2015 — Results from the multicenter, prospective, randomized PANDA III trial indicate that the BuMA sirolimus-eluting stent (SES) was non-inferior to the Excel SES for the primary endpoint of target lesion failure at one year. The trial specifically examined whether the rate of drug elution and polymer absorption affects the clinical outcomes of two bioresorbable polymer-based drug-eluting stents (DES).

Findings were reported at the 27th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF), Oct. 11-15 in San Francisco.

The PLGA polymer-based BuMA SES from SinoMed has a unique design that incorporates an electro-grafting (eG) base layer between the polymer and stent strut, securing adhesion of the PLGA coating. Sirolimus is 100 percent eluted within 30 days, and the PLGA polymer is completely absorbed within three months. In contrast, the PLA polymer-based Excel SES elutes sirolimus completely within 180 days and the PLA polymer is completely absorbed within six to nine months. Both stents elute sirolimus from a stainless steel platform, allowing for a more specific and controlled comparison of the direct effects of polymer and elution kinetics upon clinical outcomes.

PANDA III enrolled 2,348 patients randomized in a 1:1 ratio to receive a BuMA (N=1,174) or Excel (N=1,174) SES at 46 centers in China. At one-year follow-up, the primary endpoint of target lesion failure (TLF, the composite of cardiac death, target vessel myocardial infarction or ischemia-driven target lesion revascularization) was 6.4 percent for BuMA (N=1,169) and 6.4 percent for Excel (N=1,164), a difference of 0.06 percent (Pnoninferiority= 0.0003). The primary non-inferiority endpoint was met, and there were no significant differences in other major secondary endpoints. However, BuMA was also associated with a lower rate of stent thrombosis compared to JW Medical Systems’ Excel (0.5 percent vs. 1.3 percent, P=0.047). 

“Results from the PANDA III study show that the BuMA SES was non-inferior to the Excel SES for the primary endpoint of target lesion failure at one year,” said co-principal investigator Bo Xu, MBBS, director, catheterization laboratories at Fu Wai Hospital in Beijing, China.

“The BuMA SES was also associated with a lower incidence of stent thrombosis compared to the Excel SES which is consistent with previous findings of enhanced strut coverage with this device. Longer follow-up is needed to further understand the long-term effects of this emerging stent technology,” he added.

The study was funded by a research grant from SinoMed (Tianjin, China). Xu reported no relevant conflicts of interest.

For more information: www.tctconference.com

Related Content

Some of the device technologies discussed in the TCT 2020 late-breaking trial sessions. Top left, the  Medtronic Resolute Onyx stent was the first stent to receive FDA clearance for short duration dual-antiplatelet therapy, which was a big topic and subject of several sessions. Lower left, the Keystone TriGuard 3 TAVR embolic protection device did not demonstrate superiority over TAVR without use of embolic protection. Top right, the Abbott MitraClip. Acurate neo TAVR valve. #TCTconnect #TCT2020

Some of the device technologies discussed in the TCT 2020 late-breaking trial sessions. Top left, the Medtronic Resolute Onyx stent was the first stent to receive FDA clearance for short duration dual-antiplatelet therapy, which was a big topic and subject of several sessions. Lower left, the Keystone TriGuard 3 TAVR embolic protection device did not demonstrate superiority over TAVR without use of embolic protection. Top right, the Abbott MitraClip was the subject of two studies, including use to aid heart transplant patients. Bottom right, the Boston Scientific Acurate neo TAVR valve performed below the Sapien 3 and CoreValve Evolut.

Feature | TCT | October 29, 2020 | Dave Fornell, Editor
Here are some of the key takeaways from the late-breaking interventional cardiology and structural heart trials prese
TCT 2020 Late-breaking Study trial Presentations Announced. #TCTconnect #TCT2020 #TCT
Feature | TCT | October 29, 2020
October 29, 2020 — The late-breaking studies are one of the hallmarks of the annual...
Interventional cardiology and structural heart pioneer Martin Leon, M.D., is the name-sake of the new joint ACC-CRF Center for Cardiovascular Transformation. 

Interventional cardiology and structural heart pioneer Martin Leon, M.D., is the name-sake of the new joint ACC-CRF Center for Cardiovascular Transformation. 

News | TCT | October 14, 2020
October 14, 2020 — The American College of Cardiology (ACC) and the...
Videos | TCT | August 01, 2020
With COVID-19 forcing all medical conferences to go virtual in 2020,...
EchoPixel showed technology at TCT 2019 that creates live holograms in the cath lab from 3-D TEE imaging. It projects the holograms on a special display screen that does not require the user to wear 3-D glasses. The interventional cardiologist can use hand movements and a foot switch to move the image around without breaking the sterile field. It offers a new way to visualize catheters, device positioning and deployment for structural heart procedures. #TCT2019 #TCT #TCT19

EchoPixel showed technology at TCT 2019 that creates live holograms in the cath lab from 3-D TEE imaging. It projects the holograms on a special display screen that does not require the user to wear 3-D glasses. The interventional cardiologist can use hand movements and a foot switch to move the image around without breaking the sterile field. It offers a new way to visualize catheters, device positioning and deployment in structural heart procedures. (Photos by Dave Fornell)

Feature | TCT | November 04, 2019 | Dave Fornell, Editor
The latest in interventional cardiology clinical data and new device technologies were highlighted at the annual ...
TCT 2019 Late-breaking Presentations in the main arena. The top interventional cardiology studies of 2019. #TCT #TCT19 #TCT2019
Feature | TCT | October 11, 2019
The Cardiovascular Research Foundation (CRF) has announced the 12 late-breaking trials and 16 late-breaking science...
Videos | TCT | October 03, 2018
DAIC Editor Dave Fornell takes a tour of some of the most innovative new cardiovascular technology he found on the ex
cardiologist Ted Feldman, M.D., at TCT 2017. #TCT2018 #TCT #TCT18 TCT Late breaking trials, studies.
Feature | TCT | September 21, 2018
October 4, 2018 – The Cardiovascular Research Foundation (CRF) had 15 late-breaking trials and 12 late-breaking clini
Interventional cardiology, cath lab technology, TCT, transcatheter cardiovascular therapeutics. #TCT #TCT18 #TCT2018
Feature | TCT | September 14, 2018 | Dave Fornell, Editor
The volume of information attendees receive at the annual...